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OBJECTIVE — American Indians and Alaska Natives are 2.3 times more likely to have dia-
betes than are individuals in the U.S. general population. The objective of this study was to
compare morbidity among American Indian and U.S. adults with diabetes.
RESEARCH DESIGN AND METHODS — We extracted demographic and health ser-
vice utilization data for an adult American Indian population aged 18–64 years (n  30,121)
served by the Phoenix Service Unit from the Indian Health Service clinical reporting system.
Similar data for a U.S. population (n  1,500,002) with commercial health insurance, matched
by age and sex to the American Indian population, were drawn from the MartketScan Research
Database. We used Diagnostic Cost Groups to identify medical conditions for which each
individual was treated and to assign a risk score to quantify his or her morbidity burden. We
compared the prevalence of comorbidities and morbidity burden of American Indian and U.S.
adults with diabetes.
RESULTS — American Indians with diabetes had signiﬁcantly higher rates of hypertension,
cerebrovascular disease, renal failure, lower-extremity amputations, and liver disease than com-
mercially insured U.S. adults with diabetes (P  0.05). The American Indian prevalence rates
were 61.2, 6.9, 3.9, 1.8, and 7.1%, respectively. The morbidity burden among the American
Indian with diabetes exceeded that of the insured U.S. adults with diabetes by 50%.
CONCLUSIONS — The morbidity burden associated with diabetes among American Indi-
ansseenatthePhoenixServiceUnitfarexceededthatofcommerciallyinsuredU.S.adults.These
ﬁndings point to the urgency of enhancing diabetes prevention and treatment services for
American Indians/Alaska Natives to reduce diabetes-related disparities.
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A
lthough the epidemiology of diabe-
tes differs among various racial/
ethnic populations in the U.S. and
other countries, the disease burden is
considerable because of its association
withhighratesofmorbidityandmortality
and lower quality of life (1–9). Diabetes
exerts a substantial burden among Amer-
ican Indians and Alaska Natives, who are
2.3 times more likely to have diabetes
than are individuals in the U.S. general
population and who have high rates of
premature mortality (3,5,10–12). In
2004, the prevalence of diagnosed diabe-
tes among American Indians and Alaska
Natives aged 20 years was 16.3% (age-
adjusted to the U.S. general population),
and the rate is rapidly increasing (5).
To date, only a limited number of
studies have compared the prevalence of
comorbidities among American Indians
and Alaska Natives with diabetes to simi-
larratesamongotherpopulations.Higher
rates of end-stage renal disease, lower-
limb amputations, and heart disease have
been documented among American Indi-
ans and Alaska Natives with diabetes
(5,10,13–15). Many of these studies in-
cluded a limited age range of study partici-
pants, addressed only one condition, or
used previously published data to draw
comparisons between American Indians
and Alaska Natives and other populations
anddidnotincludeadjustmentsforagedif-
ferences among populations (5,10,13–15).
The Indian Health Service (IHS) pro-
vides health services to 1.9 million
American Indians and Alaska Natives
throughout the U.S. (16), including
300,000 with diabetes (5). The IHS an-
nual budget of $4.3 billion equates to
$2,300perindividual(16).Includedin
the budget are Medicaid, Medicare, and
commercial health insurance payments
for IHS services provided to American In-
dians and Alaska Natives with such cov-
erage and funds for the Special Diabetes
Program for Indians (SDPI). In 1997,
CongresspassedlegislationtocreateSDPI
to provide additional IHS funding for di-
abetes prevention and treatment pro-
grams, funding nearly 400 diabetes
programs in American Indian and Alaska
Native communities in 2007 (5). Since
the enactment of SDPI, intermediate clin-
ical outcomes (e.g., blood glucose, blood
pressure, and cholesterol levels) among
American Indians and Alaska Natives
with diabetes have improved (17), and
the rate of diabetes-related end-stage re-
nal disease has decreased (15).
Even with these improvements, dia-
betes-related disparities persist. Diabetes
isthefourthleadingcauseofdeathamong
American Indians and Alaska Natives,
and mortality due to diabetes among
American Indians and Alaska Natives is
4timeshigherthanthatoftheU.S.gen-
eral population (18). Heart disease, the
leading cause of American Indian and
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more often fatal among American Indians
than in other populations (3,10). Ameri-
can Indians and Alaska Natives have the
highest rate of premature deaths from
heart disease of all races, with 36% of
deathsfromheartdiseaseclassiﬁedaspre-
mature; the rate is nearly 2.5 times that of
whites (12). Federal and tribal policy
makers require detailed information
about the prevalence of comorbidities
among American Indians and Alaska Na-
tives with diabetes to guide prevention
and treatment strategies, and the alloca-
tion of health resources within IHS.
Here, we examined the prevalence of
a number of comorbidities among Amer-
ican Indians aged 18–64 years with
diabetes using IHS data for 30,000
AmericanIndianswhoresidedinreserva-
tion, rural, suburban, and urban areas of
central Arizona and were served by the
Phoenix Service Unit. In addition, we
compared the prevalence of comorbidi-
ties among American Indians with diabe-
tes with that of a commercially insured
U.S. population, matched by age and sex
to the American Indian population. We
quantiﬁed the overall morbidity burden
of American Indians and U.S. adults with
diabetes using Diagnostic Cost Group
(DCG) relative risk scores and compared
their burdens by age, type of diabetes
(type 1 and type 2), and cardiovascular
diseasestatustoexaminethehealthneeds
of younger and older American Indian
adults with diabetes.
RESEARCH DESIGN AND
METHODS— The American Indian
study population resided in the Phoenix
Service Unit, an IHS administrative unit
located in central Arizona. Information
concerning tribal afﬁliation is not pro-
videdas100tribesarerepresented,and
IHS does not name tribes without their
speciﬁc consent to honor tribal sover-
eignty. The Service Unit includes a large
regional hospital in Phoenix, which pro-
vides inpatient and outpatient services,
and small community-based clinics dis-
persed throughout the region. The Ser-
viceUnitusesauniﬁedelectronicmedical
record and registration system, the Re-
source Patient Management System,
which includes detailed administrative
andclinicalinformationsimilartoadmin-
istrative claims for a commercial health
insurance plan (19).
The American Indian study popula-
tion included adults aged 18–64 years
who were active users of IHS services be-
tween 1 October 2004 and 30 September
2005 (ﬁscal year [FY] 2005), reported the
Phoenix Service Unit as their community
of residence during FY 2005, and did not
have Medicare coverage. The IHS deﬁni-
tionofanactiveuserduringaﬁscalyearis
a individual who had at least one outpa-
tientvisitduring1ofthepast3ﬁscalyears
(FY 2003–2005 in this study). Because
theinsuredU.S.studypopulationdidnot
include individuals with Medicare cover-
age, the American Indian study popula-
tion excluded individuals aged 18–64
yearswithMedicarecoverage(n1,931)
and individuals aged 65 (n  1,113).
The resulting sample size was 30,121.
The insured U.S. study population
was drawn from the 2005 MartketScan
Research Database produced by Thom-
sonHealthcare,adatabaseof13.2million
people with commercial health insurance
of all major beneﬁt types (fee-for-service,
preferred provider organizations, and
HMOs) (20,21). We identiﬁed a popula-
tion sample from MarketScan that in-
cluded adults aged 18–64 years with
documented health coverage for medical
and pharmacy services for 24 months be-
tweenJanuary2004andDecember2005.
Although we analyzed data for 2005, the
inclusion criterion regarding 2004 data
limited missing data associated with cov-
erage changes. For example, if a individ-
ual started new coverage in 2004 that
including a clause limiting coverage for
preexisting conditions, the 2004 data
may not include information on all of his
or her conditions. The commercially in-
sured U.S. adults (hereafter referred to
as the U.S. study population, n 
1,500,002), a subset of the MarketScan
sample, was matched with the American
Indian study population by age (mea-
sured in years) and sex. We selected Mar-
ketScan as the comparison population for
four key reasons: 1) the sample size al-
lowed for a U.S. sample to be drawn to
match the American Indian population;
2) the population had commercial health
insurance coverage; 3) the administrative
claims data had ICD-9 diagnostic codes
from medical service records similar to
the IHS data, and 4) DCG models could
be used to assess the health status of both
populations. The IHS Phoenix Area Insti-
tutional Review Board and the University
of Colorado Denver Institutional Review
Board approved the study protocol.
Data
For the American Indian study popula-
tion, we extracted data from IHS data-
bases on age, sex, and utilization of
services in Arizona, Utah, Nevada, and
California during FY 2005. Similar to ad-
ministrative claims of private insurance
companies, the IHS records included
information on medical procedures, di-
agnostic codes, place of service, and
volume. IHS refers patients to non-IHS
facilities for specialty services not pro-
vided at the IHS facilities; much of this
care is paid for through IHS Contract
Health Services. We obtained Contract
Health claims data from the IHS ﬁscal
intermediary, Blue Cross Blue Shield
New Mexico.
For the U.S. study population, we
extracted similar data for calendar year
2005 from MarketScan. The U.S. study
population was drawn to match the
American Indian study population by sex
and age-groups in 5-year age bands using
bootstrapping with 100 iterations; the re-
sulting ratio of U.S. to American Indian
adults was 50:1. Given the lower preva-
lence of diabetes in the U.S. study popu-
lation, the ratio of U.S. to American
Indian adults with diabetes was 11.6:1.
The ratio allowed for the assessment of
comorbidities among U.S. and American
Indian adults, including those who have
a low prevalence, by age-group. Mar-
ketScan did not include measures of race/
ethnicity or household income.
Analysis
Although the insured U.S. study popula-
tion was matched by age and sex to the
American Indian study population, the
age distribution of the American Indian
and U.S. adults with diabetes differed. To
comparethehealthstatusoftheAmerican
Indian and U.S. adults with diabetes, age-
adjustedratesfortheU.S.adultswerecal-
culated by the direct method using the
age distribution of the American Indian
adults with diabetes.
We used Risksmart (21) software to
identify diagnosed conditions among
the American Indian and U.S. adults.
Risksmart classiﬁes the ICD-9-CM diag-
nostic codes entered on records for inpa-
tient and outpatient services (excluding
records for laboratory services) into 781
Diagnostic Groups, 184 Hierarchical
Condition Categories, and 30 Aggregated
Condition Categories. We assessed the
prevalenceofdiabetesandrelatedcomor-
bidities using combinations of these
groupings. We compared the Risksmart
software data quality reports for the
American Indian and U.S. data and found
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to diagnostic quality indicators.
DCG models use hierarchical algo-
rithms to assign relative risk scores based
on age, sex, and identiﬁed acute and
chronic conditions. DCG Model 18, an
all-encounter diagnosis model for com-
merciallyinsuredindividuals,wasusedto
assignarelativeriskscoretoeachindivid-
ual. The score is a continuous variable
typically ranging from a very small posi-
tive value for the healthiest individuals to
100 for the sickest. A higher risk score
indicates higher morbidity burden or ex-
pected health resource use. For example,
the relative risk scores for a 30-year-old
man and a 50-year-old man with diabetes
butnoothercomorbiditieswere0.79and
1.09, respectively, whereas that for a 50-
year-old man with diabetes, congestive
heart failure, and depression was 2.95.
The risk score correlates with a individu-
al’sexpectedhealthserviceutilizationand
health spending for a 12-month period,
compared with the average for a U.S.
commercial population. The risk score
can be converted to a dollar amount that
represents a person’s expected health re-
sourceuseduringthe12-monthperiod.A
relativeriskof1.0intheMarketScanpop-
ulation translated in 2005 to $3,050 in
medical and pharmacy spending (inclu-
sive of health plan reimbursement, co-
payments, and deductibles), whereas a
relative risk score of 3.0 translated to
$9,150.
We used DCGs in this study because
federal agencies (e.g., Centers for Medi-
care and Medicaid Services and Agency
for Healthcare Research and Quality),
state governments, and commercial in-
surance companies use DCG models to
assess the morbidity burden of popula-
tions (22–24). In addition, the models
were highly ranked by the Society of Ac-
tuaries in their comparative study of sim-
ilar software tools (24).
RESULTS— The American Indian
study population included a higher per-
centageofwomenandalowerpercentage
of older adults than the MarketScan pop-
ulation sample that met the inclusion cri-
teria. Only 4.8% of the American Indian
adults were aged 55–64 years compared
with18.0%oftheMarketScanpopulation
sample. The U.S. study population was
drawn from this MarketScan population
sample, matched by age and sex to the
American Indian study population. The
ﬁndings presented in Tables 1–3 are for
the American Indian adults and the U.S.
study population.
The rate of diabetes was 3 times
higheramongtheAmericanIndianadults
than among the U.S. adults (Table 1).
More than 9% of American Indian adults
had diabetes compared with 2.6% of U.S.
adults (P  0.05). Differences were ob-
served across every age-group. The age
distributionsofAmericanIndianandU.S.
adultswithdiabetesdiffered;thepercent-
ages of American Indian and U.S. adults
withdiabetesaged55–64yearswere17.5
and 22.5%, respectively. Whereas the
prevalence of type 1 diabetes was statisti-
cally higher among U.S. adults (0.5% of
U.S.adultscomparedwith0.4%ofAmer-
ican Indian adults; P  0.05), the preva-
lenceoftype2diabeteswashigheramong
American Indian adults in every age-
group (P  0.05).
Table2includestheprevalenceofco-
morbiditiesamongadultswithdiabetesas
well as age-adjusted prevalence rates be-
cause of the noted differences in the age
distribution of American Indian and U.S.
adults with diabetes. (Similar results are
available by type from the authors.)
Among American Indian adults with dia-
betes, the prevalence of hypertension
ranged from 40.5% for those aged 18–34
years to 79.3% among those aged 55–64
years. The prevalence among all Ameri-
can Indian adults with diabetes was
61.2%—a rate nearly double the age-
adjusted prevalence rate for U.S. adults
with diabetes (31.5%; P  0.05). The
prevalenceofcerebrovasculardiseasewas
higher among American Indian adults
with diabetes than among U.S. adults
withdiabetes(6.9and5.5%,respectively;
Table1—PrevalenceofdiabetesamongAmericanIndianadultsfromcentralArizonaandcommerciallyinsuredU.S.adultsaged18–64years
American Indian adults from
central Arizona Commercially insured U.S. adults
Ratio of the prevalence
of diabetes among
American Indian and
U.S. adults n Diabetes 95% CI n Diabetes CI
All individuals with diabetes
18–34 years 18,723 718 (3.8) 3.6–4.1 932,392 10,011 (1.1) 1.1–1.1* 3.6
35–44 years 6,429 784 (12.2) 11.4–13.0 320,158 9,735 (3.0) 3.0–3.1* 4.0
45–54 years 3,509 802 (22.9) 21.5–24.2 174,744 10,736 (6.1) 6.0–6.3* 3.7
55–64 years 1,460 489 (33.5) 31.1–35.9 72,708 8,868 (12.2) 12.0–12.4* 2.7
All ages 30,121 2,793 (9.3) 8.9–9.6 1,500,002 39,350 (2.6) 2.6–2.6* 3.5
Individuals with type 1 diabetes
18–34 years 18,723 45 (0.2) 0.2–0.3 932,392 3,751 (0.4) 0.4–0.4* 0.6
35–44 years 6,429 35 (0.5) 0.4–0.7 320,158 1,906 (0.6) 0.6–0.6 0.9
45–54 years 3,509 15 (0.4) 0.2–0.6 174,744 1,454 (0.8) 0.8–0.9* 0.5
55–64 years 1,460 12 (0.8) 0.4–1.3 72,708 1,086 (1.5) 1.4–1.6* 0.6
All ages 30,121 107 (0.4) 0.3–0.4 1,500,002 8,197 (0.5) 0.5–0.6* 0.7
Individuals with type 2 diabetes
18–34 years 18,723 673 (3.6) 3.3–3.9 932,392 6,260 (0.7) 0.7–0.7* 5.4
35–44 years 6,429 749 (11.7) 10.9–12.4 320,158 7,829 (2.4) 2.4–2.5* 4.8
45–54 years 3,509 787 (22.4) 21.0–23.8 174,744 9,282 (5.3) 5.2–5.4* 4.2
55–64 years 1,460 477 (32.7) 30.3–35.1 72,708 7,782 (10.7) 10.5–10.9* 3.1
All ages 30,121 2,686 (8.9) 8.6–9.2 1,500,002 31,153 (2.1) 2.1–2.1* 4.3
Data are n, n (%), or CI calculated at 95% conﬁdence. *Indicates signiﬁcance at the 0.05 level.
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years with diabetes
Condition and age group
American Indian adults from central
Arizona with diabetes
Commercially insured U.S. adults
with diabetes
Ratio of the prevalence
of comorbidities among
American Indian and
U.S. adults with diabetes n (diabetes) Condition CI n (diabetes) Condition CI
Hypertension
18–34 years 718 291 (40.5) 36.9–44.1 10,011 1,450 (14.5) 13.8–15.2*
35–44 years 784 452 (57.7) 54.2–61.1 9,735 2,879 (29.6) 28.7–30.5*
45–54 years 802 577 (71.9) 68.8–75.1 10,736 4,234 (39.4) 38.5–40.4*
55–64 years 489 388 (79.3) 75.8–82.9 8,868 4,115 (46.4) 45.4–47.4*
All ages 2,793 1,708 (61.2) 59.3–63.0 39,350 12,678 (32.2) 31.8–32.7* 1.9
All ages with age adjustment† (31.5) 31.1–31.9* 1.9
Cerebrovascular disease
18–34 years 718 31 (4.3) 2.8–5.8 10,011 272 (2.7) 2.4–3.0
35–44 years 784 47 (6.0) 4.3–7.7 9,735 355 (3.6) 3.3–4.0*
45–54 years 802 61 (7.6) 5.8–9.4 10,736 724 (6.7) 6.3–7.2
55–64 years 489 53 (10.8) 8.1–13.6 8,868 953 (10.7) 10.1–11.4
All ages 2,793 192 (6.9) 5.9–7.8 39,350 2,304 (5.9) 5.6–6.1 1.2
All ages with age adjustment† (5.5) 5.3–5.7* 1.2
Ischemic heart disease
18–34 years 718 26 (3.6) 2.3–5.0 10,011 162 (1.6) 1.4–1.9*
35–44 years 784 33 (4.2) 2.8–5.6 9,735 403 (4.1) 3.7–4.5
45–54 years 802 47 (5.9) 4.2–7.5 10,736 994 (9.3) 8.7–9.8*
55–64 years 489 49 (10.0) 7.4–12.7 8,868 1,494 (16.8) 16.1–17.6*
All ages 2,793 155 (5.5) 4.7–6.4 39,350 3,053 (7.8) 7.5–8.0* 0.7
All ages with age adjustment† (7.2) 7.0–7.4* 0.8
Other forms of heart disease
18–34 years 718 37 (5.2) 3.5–6.8 10,011 315 (3.1) 2.8–3.5
35–44 years 784 33 (4.2) 2.8–5.6 9,735 461 (4.7) 4.3–5.2
45–54 years 802 40 (5.0) 3.5–6.5 10,736 810 (7.5) 7.0–8.0*
55–64 years 489 34 (7.0) 4.7–9.2 8,868 1,176 (13.3) 12.6–14.0*
All ages 2,793 144 (5.2) 4.3–6.0 39,350 2,762 (7.0) 6.8–7.3* 0.7
All ages with age adjustment† (6.6) 6.4–6.8* 0.8
CVD
18–34 years 718 68 (9.5) 7.3–11.6 10,011 645 (6.4) 6.0–6.9*
35–44 years 784 87 (11.1) 8.9–13.3 9,735 1,012 (10.4) 9.8–11.0
45–54 years 802 124 (15.5) 13.0–18.0 10,736 1,982 (18.5) 17.7–19.2
55–64 years 489 103 (21.1) 17.4–24.7 8,868 2,590 (29.2) 28.3–30.2*
All ages 2,793 382 (13.7) 12.4–15.0 39,350 6,229 (15.8) 15.5–16.2* 0.9
All ages with age adjustment† (15.0) 14.7–15.3 0.9
Renal failure
18–34 years 718 25 (3.5) 2.1–4.8 10,011 105 (1.0) 0.8–1.2*
35–44 years 784 25 (3.2) 2.0–4.4 9,735 194 (2.0) 1.7–2.3
45–54 years 802 34 (4.2) 2.8–5.6 10,736 270 (2.5) 2.2–2.8
55–64 years 489 26 (5.3) 3.3–7.3 8,868 364 (4.1) 3.7–4.5
All ages 2,793 110 (3.9) 3.2–4.7 39,350 933 (2.4) 2.2–2.5* 1.7
All ages with age adjustment† (2.3) 2.2–2.4* 1.7
Neuropathy
18–34 years 718 71 (9.9) 7.7–12.1 10,011 634 (6.3) 5.9–6.8*
35–44 years 784 129 (16.5) 13.9–19.0 9,735 773 (7.9) 7.4–8.5*
45–54 years 802 145 (18.1) 15.4–20.7 10,736 874 (8.1) 7.6–8.7*
55–64 years 489 123 (25.2) 21.3–29.0 8,868 689 (7.8) 7.2–8.3*
All ages 2,793 468 (16.8) 15.4–18.1 39,350 2,970 (7.5) 7.3–7.8* 2.2
All ages with age adjustment† (7.6) 7.3–7.9* 2.2
Amputations
18–34 years 718 6 (0.8) 0.2–1.5 10,011 3 (0.0) 0.0–0.1
35–44 years 784 13 (1.7) 0.8–2.6 9,735 13 (0.1) 0.1–0.2
(continued)
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emic heart disease and other types of
heart disease was lower among the Amer-
ican Indian adults (5.5 and 5.2%, respec-
tively,amongAmericanIndianadultsand
7.2 and 6.6% among U.S. adults; P 
0.05). We deﬁned cardiovascular disease
(CVD)toincludecerebrovasculardisease,
ischemicheartdisease,andotherformsof
heart disease. The prevalence of CVD was
signiﬁcantly higher among younger
American Indian adults with diabetes
(those aged 18–34 years) than among
youngerU.S.adultswithdiabetes.Incon-
trast,CVDwaslessprevalentamongolder
American Indian adults with diabetes
(aged 55–64 years).
American Indian adults with diabetes
were signiﬁcantly more likely to have re-
nal failure, lower-extremity amputations,
and neuropathy than were U.S. adults
with diabetes. The rate for amputations
among American Indian adults was 10
times that of U.S. adults. Mental health
disorders and liver disease were approxi-
mately twice as prevalent among Ameri-
can Indian adults. For example, 19.2% of
all American Indian adults with diabetes
had a mental health disorder (e.g., de-
pression or anxiety) compared with
10.4% of all U.S. adults (P  0.05); the
difference was most pronounced at older
ages. The prevalence of liver disease was
7.1% among American Indian adults and
3.4% among U.S. adults (P  0.05); vari-
ations by age were not observed. Sub-
stance abuse (e.g., alcohol and drug use
disorders) was also more prevalent
among American Indian adults.
The mean DCG relative risk score for
AmericanIndianadultsaged18–64years
with diabetes was 5.4 (Table 3). In other
words, their risk for use of health re-
sources was 5 times that of an average
U.S. adult with commercial insurance.
The mean relative risk among American
Indian adults with diabetes was 50%
higher than that of U.S. adults with dia-
betes, for whom the age-adjusted mean
risk was 3.6 (P  0.05). This result sug-
gests that, controlling for age and sex,
American Indian adults with diabetes
were at 50% greater risk for health re-
source use than U.S. adults with diabetes
because of the presence of other health
conditions.Adultswithbothdiabetesand
CVD had higher risk than adults with di-
abetes but not CVD. The relative risk of
AmericanIndianadultswithdiabetesand
CVD was 13.3, 40% higher than the
risk among U.S. adults with both
conditions.
CONCLUSIONS — We documented
the higher prevalence of comorbidities,
including hypertension, cerebrovascular
disease, lower-extremity amputations,
mentalhealthdisorders,andliverdisease,
among American Indian adults with dia-
betes living in central Arizona compared
with those of a sample of commercially
insured U.S. adults with diabetes. These
comorbidities not only complicate diabe-
tes treatment and inﬂuence a individual’s
ability to manage his or her own diabetes
Table 2—Continued
Condition and age group
American Indian adults from central
Arizona with diabetes
Commercially insured U.S. adults
with diabetes
Ratio of the prevalence
of comorbidities among
American Indian and
U.S. adults with diabetes n (diabetes) Condition CI n (diabetes) Condition CI
45–54 years 802 15 (1.9) 0.9–2.8 10,736 17 (0.2) 0.1–0.2
55–64 years 489 15 (3.1) 1.5–4.6 8,868 15 (0.2) 0.1–0.3
All ages 2,793 49 (1.8) 1.3–2.2 39,350 48 (0.1) 0.1–0.2* 14.4
All ages with age adjustment† (0.1) 0.1–0.2* 14.4
Mental health disorders‡
18–34 years 718 114 (15.9) 13.2–18.6 10,011 1,145 (11.4) 10.8–12.1*
35–44 years 784 171 (21.8) 18.9–24.7 9,735 1,125 (11.6) 10.9–12.2*
45–54 years 802 167 (20.8) 18.0–23.6 10,736 1,068 (9.9) 9.4–10.5*
55–64 years 489 84 (17.2) 13.8–20.5 8,868 688 (7.8) 7.2–8.3*
All ages 2,793 536 (19.2) 17.7–20.7 39,350 4,026 (10.2) 9.9–10.5* 1.9
All ages with age adjustment† (10.4) 10.1–10.7* 1.8
Substance abuse§
18–34 years 718 73 (10.2) 8.0–12.4 10,011 96 (1.0) 0.8–1.1*
35–44 years 784 127 (16.2) 13.6–18.8 9,735 73 (0.7) 0.6–0.9*
45–54 years 802 102 (12.7) 10.4–15.0 10,736 83 (0.8) 0.6–0.9*
55–64 years 489 31 (6.3) 4.2–8.5 8,868 50 (0.6) 0.4–0.7*
All ages 2,793 333 (11.9) 10.7–13.1 39,350 302 (0.8) 0.7–0.9* 15.5
All ages with age adjustment† (0.8) 0.7–0.9* 14.9
Liver disease
18–34 years 718 45 (6.3) 4.5–8.0 10,011 288 (2.9) 2.5–3.2*
35–44 years 784 63 (8.0) 6.1–9.9 9,735 307 (3.2) 2.8–3.5*
45–54 years 802 57 (7.1) 5.3–8.9 10,736 429 (4.0) 3.6–4.4*
55–64 years 489 34 (7.0) 4.7–9.2 8,868 335 (3.8) 3.4–4.2*
All ages 2,793 199 (7.1) 6.2–8.1 39,350 1,359 (3.5) 3.3–3.6* 2.1
All ages with age adjustment† (3.4) 3.2–3.6* 2.1
Data are n, n (%), or CI calculated at 95% conﬁdence. *Indicates signiﬁcance at the 0.05 level. †The age distribution of the commercially insured U.S. adults with
diabetesdifferedfromtheagedistributionoftheAmericanIndianadultswithdiabetes.Forthisreason,wecalculatedage-adjustedratesforthecommerciallyinsured
U.S. adults with diabetes for each condition. ‡Mental health disorders include a broad array of disorders such as depression, posttraumatic stress, anxiety, and other
mental disorders. §Substance abuse includes alcohol and drug use disorders and psychoses and excludes tobacco use disorders.
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of life and higher mortality.
The morbidity burden among the
American Indian with diabetes exceeded
that of the U.S. adults with diabetes by
50%. Accordingly, American Indian
adults with diabetes in this study would
be expected to use 50% more health re-
sources than U.S. adults with diabetes
and commercial insurance. The magni-
tude of increased risk among American
Indians with diabetes remained fairly
constant across all ages. Using the 2005
MarketScan health expenditure for an
adult with average risk ($3,050), a U.S.
adult with diabetes was estimated to cost
$12,800 during 2005 and an American
Indian adult with diabetes $19,260.
The IHS was the primary provider of
medical services for the American Indian
adults included in this study. Service de-
livery and treatment costs within the IHS
differfromservicesaccessedintheprivate
sector. Consequently, MarketScan health
expenditure estimates are not directly
comparable to IHS health expenditures.
However, the ﬁndings concerning the ex-
ceedingly higher risk of American Indian
adults with diabetes may be used to eval-
uate the ﬁnancial resources available to
meet treatment needs of American Indi-
ans with diabetes.
Furthermore, the ﬁndings may be
used to inform efforts to enhance preven-
tion and treatment programs, particularly
programs to prevent complications
among American Indians with diabetes.
The ﬁndings document the need for
strong linkages between behavioral and
physical health providers for younger
adults with diabetes. CVD was prevalent
among American Indian and U.S. adults
with diabetes, yet the morbidity burden
among American Indian adults with both
diabetesandCVDwas40%higherthan
that of U.S. adults with both conditions.
Given the high rates of premature death
from heart disease among American Indi-
ans and Alaska Natives, the speciﬁc treat-
ment needs of these patients should be
explored.Finally,DCGriskscoresmaybe
usedtotargetinterventionsforthosewith
extremely high risk to reduce the likeli-
hood of additional complications associ-
ated with diabetes.
This is the ﬁrst study to compare the
prevalence of several comorbidities and
theoverallmorbidityburdenofAmerican
Indian adults with diabetes with those for
commerciallyinsuredU.S.adultswithdi-
abetes, controlling for age differences.
However, it is important to note several
limitations. First, the study included data
for only IHS active users. Still, they rep-
resent a very large proportion of individ-
ualseligibleforIHSservicesintheService
Unit (25). Second, we analyzed American
Indian data for services obtained at non-
IHS facilities if IHS provided payment for
the services through Contract Health Ser-
vices.Consequently,wedidnothavedata
with the diagnostic codes for services not
reimbursed by IHS. This may have biased
downward the prevalence rates of diabe-
tes and other conditions (e.g., heart dis-
ease)reportedforAmericanIndianadults
in this study.
Third, we chose a U.S. adult popula-
tion with commercial health insurance as
ourcomparisonpopulation.Althoughthe
Table 3—DCG relative risk scores for American Indian adults from central Arizona and
commerciallyinsuredU.S.adultsaged18–64yearswithdiabetesbyage,typeofdiabetes,and
cardiovascular disease status
Age group
American Indian
adults from
central Arizona
with diabetes
Commercially
insured
U.S. adults
with diabetes
Ratio of relative
risk scores for
American Indian
and U.S. adults
with diabetes*
All individuals with diabetes
18–34 years 4.8 (4.3–5.3) 3.2 (3.1–3.3)† 1.5
35–44 years 5.1 (4.6–5.6) 3.2 (3.1–3.3)† 1.6
45–54 years 5.7 (5.2–6.2) 3.7 (3.6–3.8)† 1.5
55–64 years 6.0 (5.4–6.5) 4.5 (4.4–4.7)† 1.3
All ages 5.4 (5.1–5.6) 3.6 (3.6–3.7)† 1.5
All ages with age adjustment‡ 3.6 (3.5–3.6)† 1.5
Type of diabetes
Type 1 diabetes
18–34 years 8.9 (5.7–12.1) 3.5 (3.3–3.7)†
35–44 years 10.9 (6.7–15.2) 4.6 (4.3–5.0)†
45–54 years 15.6 (6.7–24.6) 6.3 (5.8–6.7)†
55–64 years 19.3 (10.6–28.1) 7.7 (7.1–8.4)†
All ages 11.7 (9.2–14.1) 4.8 (4.6–5.0)† 2.4
All ages with age adjustment‡ 4.7 (4.6–4.9)† 2.5
Type 2 diabetes
18–34 years 4.5 (4.1–5.0) 3.0 (2.8–3.1)†
35–44 years 4.9 (4.4–5.3) 2.8 (2.7–2.9)†
45–54 years 5.5 (5.1–5.9) 3.3 (3.2–3.4)†
55–64 years 5.6 (5.1–6.2) 4.1 (4.0–4.2)†
All ages 5.1 (4.9–5.3) 3.3 (3.2–3.4)† 1.5
All ages with age adjustment‡ 3.2 (3.2–3.3)† 1.6
CVD status
Diabetes with CVD
18–34 years 14.8 (11.4–18.2) 10.2 (9.3–11.2)†
35–44 years 15.6 (12.2–18.9) 9.6 (8.8–10.3)†
45–54 years 12.3 (10.3–14.3) 8.9 (8.4–9.4)†
55–64 years 11.5 (9.6–13.3) 9.1 (8.7–9.5)†
All ages 13.3 (12.0–14.5) 9.2 (8.9–9.5)† 1.4
All ages with age adjustment‡ 9.3 (9.0–9.6)† 1.4
Diabetes without CVD
18–34 years 3.8 (3.5–4.1) 2.7 (2.6–2.7)†
35–44 years 3.8 (3.5–4.1) 2.4 (2.4–2.5)†
45–54 years 4.5 (4.1–4.8) 2.5 (2.4–2.6)†
55–64 years 4.5 (4.1–4.9) 2.7 (2.6–2.7)†
All ages 4.1 (3.9–4.3) 2.6 (2.5–2.6)† 1.6
All ages with age adjustment‡ 2.6 (2.5–2.6)† 1.6
Data are means (CI) calculated at 95% conﬁdence. *The ratio of DCG relative risk scores was calculated by
dividingthemeanAmericanIndianadultriskscorebythemeanU.S.adultriskscore.†Signiﬁcantatthe0.05
level. ‡The age distribution of the commercially insured U.S. adults with diabetes differed from the age
distributionoftheAmericanIndianadultswithdiabetes.Forthisreason,wecalculatedage-adjustedratesfor
the commercially insured U.S. adults with diabetes.
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ketScan adult sample was similar to the
estimated prevalence among U.S. adults
aged 18–64 years (7), we recognize that
the average household income of com-
mercially insured U.S. adults exceeded
that of the American Indian population,
who may have had an average household
income closer to that of Medicaid and
uninsured populations. Adults with
lower incomes and nonmajority ethnic
and racial backgrounds are often less
likely to use medical services for several
reasons including ﬁnancial and geo-
graphic access, culture, and discrimina-
tion. MarketScan does not include data
forindividualswithMedicaidorMedicare
coverage or uninsured individuals. We
did not consider using a Medicaid popu-
lation as a comparison population be-
cause the age and sex distributions of
adult Medicaid populations, which are
drivenbyeligibilitycategories,differfrom
thoseoftheAmericanIndianadults.With
limited ﬁnancial access to medical ser-
vices, the diagnostic codes recorded in
claimsdataforuninsuredindividualsmay
underestimate their disease burden. We
believe the diagnostic codes recorded in
the MarketScan data are a reasonable in-
dicator of the health status of the com-
mercially insured U.S. study population.
ThedifferencesbetweentheAmericanIn-
dian and the U.S. adults observed in this
study are undoubtedly larger than would
be differences between American Indians
and a representative U.S. population that
included adults with lower incomes and
in poorer health than the commercially
insured adults. We were unable to iden-
tify data for a representative U.S. sample
that is comparable to the IHS data. We
concluded that the strengths of the Mar-
ketScan data (e.g., a large sample that al-
lowed for a study of comorbidities among
individuals with diabetes and the ability
touseDCGmodelstoidentifycomorbidi-
ties and to quantify the morbidity bur-
den)farexceededthelimitationsinherent
in its use.
Fourth, we extracted data for some-
what different time periods for the Amer-
ican Indian adults (FY 2005) and U.S.
adults (calendar year 2005). We believe
thisdifferencehadminimalimpactonthe
ﬁndings. For both study populations,
prevalence rates were based on adminis-
trative data for one 12-month period and
most likely underestimated actual preva-
lence rates. Finally, this study provides
important information concerning mor-
bidity for nearly 2,800 American Indian
adults in central Arizona with diabetes.
However,thereare550federallyrecog-
nized tribes throughout the U.S. and
tribalvariationsinculture,traditions,his-
tory, and the prevalence of diabetes are
well documented (5,25). For example,
the diabetes prevalence among all Amer-
ican Indian adults in the Phoenix Service
Unit, including those with Medicare cov-
erage and aged 65 years, was 10.9%
during FY 2005, a rate that is consistent
with previous IHS estimates. During
2004, the prevalence among American
Indians and Alaska Natives aged 20
years was 10% in Alaska and 20% in
North Dakota (5). Consequently, these
results may not be generalizable to other
American Indian and Alaska Native pop-
ulations and additional studies are
needed.
The morbidity burden among Amer-
ican Indians with diabetes far exceeded
that of commercially insured U.S. adults
with diabetes. The information concern-
ing the prevalence of comorbidities
among American Indians with diabetes
may inform government and tribal efforts
to enhance diabetes prevention and treat-
ment and ultimately reduce disparities
between American Indian and U.S. pop-
ulations in diabetes-related morbidity
and premature mortality.
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